Gujarat Terce Laboratories Share Price | Gujarat Terce Laboratories Stock Screener
GUJTERC
Pharmaceuticals
Share Price BSE
₹34.71
▼
-0.29 (-0.83%)
As of May 21, 2026, the Gujarat Terce Laboratories share price (BSE: GUJTERC) is ₹34.71, down 0.83% from the previous close, with shares trading between ₹34.70 and ₹36.00, and a 52-week range of ₹30.90–₹58.49.
Check Gujarat Terce Laboratories 52-week for the annual price range and momentum.
Use the Gujarat Terce Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Gujarat Terce Laboratories Market Cap
₹28.43 Cr.
GUJTERC P/E Ratio (TTM)
15.00
Gujarat Terce Laboratories P/B Ratio
3.36
EPS (TTM)
₹-1.32
Dividend Yield
-
Debt to Equity
0.35
GUJTERC 52 Week High
₹58.49
Gujarat Terce Laboratories 52 Week Low
₹30.90
Operating Margin
16.00%
Profit Margin
20.00%
GUJTERC Revenue (TTM)
₹10.00
EBITDA
₹2.00
Net Income
₹2.00
Total Assets
₹23.00
Total Equity
₹7.00
Gujarat Terce Laboratories Share Price Chart
Screen Gujarat Terce Laboratories share price with an interactive chart. Analyse GUJTERC price trends and volatility across different timeframes.
Gujarat Terce Laboratories Company Profile - Fundamental Screener
Screen Gujarat Terce Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for GUJTERC shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE499G01013
Gujarat Terce Laboratories Balance Sheet Screener
Screen GUJTERC balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 23 | 23 | 29 | 27 | 22 | 23 | 19 | 20 | 24 | 25 |
| Current Assets | 12 | 11 | 16 | 16 | 12 | 12 | 9 | 10 | 13 | 15 |
| Fixed Assets | 4 | 4 | 4 | 4 | 3 | 2 | 2 | 2 | 6 | 6 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 4 | 4 | 5 | 6 | 3 | 2 | 2 | 2 | 8 | 8 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 7 | 7 | 7 | 9 | 8 | 11 | 11 | 10 | 10 | 10 |
| Share Capital | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 |
| Reserves & Surplus | -1 | 0 | -1 | 1 | 0 | 4 | 3 | 3 | 3 | 3 |
Gujarat Terce Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen Gujarat Terce Laboratories income statement and profit fundamentals.
Analyze GUJTERC quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Gujarat Terce Laboratories share price evaluation.
| Item | 2021-Jun | 2021-Sept | 2020-Mar | 2020-Jun | 2020-Sept | 2019-Mar | 2019-Jun | 2019-Sept | 2019-Dec | 2018-Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10 | 10 | 10 | 5 | 7 | 8 | 7 | 11 | 10 | 8 |
| Expenses | 8 | 10 | 10 | 5 | 7 | 8 | 8 | 9 | 10 | 8 |
| EBITDA | 2 | 1 | 0 | 0 | 0 | 0 | -1 | 2 | 1 | 1 |
| Operating Profit % | 16.00% | 5.00% | -5.00% | -8.00% | 2.00% | 2.00% | -16.00% | 17.00% | 4.00% | 8.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 2 | 0 | 0 | 0 | 0 | 0 | -1 | 2 | 0 | 1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 2 | 0 | -1 | 0 | 0 | 0 | -1 | 2 | 0 | 1 |
| EPS | 2.16 | 0.61 | 0.00 | -0.60 | -0.02 | 0.49 | 0.00 | 2.28 | 0.50 | 0.77 |
Gujarat Terce Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen GUJTERC cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3 | 3 | 0 | 0 | 0 | -2 | -1 | 5 | 0 | 0 |
| Investing Activities | 1 | -1 | 1 | -1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Financing Activities | -3 | -4 | 0 | 2 | 2 | 2 | 0 | -5 | 0 | -1 |
| Net Cash Flow | 1 | -2 | 1 | 0 | 1 | 0 | -1 | 0 | 0 | -1 |
Gujarat Terce Laboratories Shareholding Pattern Screener
See Gujarat Terce Laboratories shareholding pattern with promoter, FII, and DII holdings.
Check Gujarat Terce Laboratories promoter holding and ownership changes for GUJTERC on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 40.03% | 37.03% | 37.03% | 37.03% | 40.03% | 37.03% | 37.03% | 37.03% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 54.58% | 59.34% | 59.12% | 58.49% | 54.43% | 59.92% | 59.87% | 59.62% |
| Other Holding | 5.39% | 3.63% | 3.85% | 4.48% | 5.54% | 3.05% | 3.10% | 3.35% |
| Shareholder Count | 13,750 | 13,764 | 13,804 | 13,812 | 13,812 | 13,203 | 13,394 | 13,538 |
Gujarat Terce Laboratories Share Dividend Screener - Share Yield Analysis
Check Gujarat Terce Laboratories dividend history with payout and yield data.
View Gujarat Terce Laboratories dividend details including ex-dates and amounts for GUJTERC stock.
Gujarat Terce Laboratories Stock Index Membership
See which indices include Gujarat Terce Laboratories stock.
Check GUJTERC index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Gujarat Terce Laboratories Market Events Screener - Corporate Actions
Get Gujarat Terce Laboratories corporate actions including splits, bonuses, and buybacks.
Check Gujarat Terce Laboratories stock events that may affect GUJTERC share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 42.75% | ||
| 2026-02-04 | 2026-02-04 | Quarterly Result Announcement | NA | -10.05% |
| 2025-11-08 | 2025-11-08 | Quarterly Result Announcement | NA | 0.50% |
| 2025-08-21 | 2025-08-21 | Annual General Meeting | NA | -11.91% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | -3.34% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | -2.57% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | -6.07% |
| 2024-10-28 | 2024-10-28 | Quarterly Result Announcement | NA | -9.08% |
| 2024-04-25 | 2024-04-25 | Extraordinary General Meeting | NA | 27.38% |
Gujarat Terce Laboratories Competitors Screener - Peer Comparison
Screen GUJTERC competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 450,643 | 40.81 | 54,729 | 9.71% | 10,980 | 64.89 |
| Divis Laboratories | 179,470 | 74.13 | 9,712 | 18.67% | 2,191 | 64.06 |
| Torrent Pharmaceuticals | 149,109 | 65.68 | 11,539 | 6.99% | 1,911 | 58.52 |
| Cipla | 115,682 | 30.09 | 27,712 | -2.46% | 3,783 | 69.78 |
| Dr Reddys Laboratories | 111,567 | 26.16 | 33,593 | -0.44% | 3,998 | 59.87 |
| Lupin | 104,032 | 19.28 | 27,488 | 19.98% | 5,345 | 46.11 |
| Mankind Pharma | 103,325 | 56.36 | 12,744 | 20.90% | 2,007 | 73.37 |
| Zydus Life Science | 101,801 | 19.85 | 23,511 | 18.55% | 4,615 | 69.47 |
| Aurobindo Pharma | 87,806 | 25.16 | 32,346 | 9.43% | 3,484 | 73.83 |
| Laurus Labs | 71,455 | 79.78 | 6,813 | 21.03% | 884 | 80.26 |
Gujarat Terce Laboratories Company Announcements - News Screener
Screen GUJTERC latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-20 | Board Meeting Intimation for Consideration Of Annual Audited Standalone Financial Results Of The Company For The Fourth Quarter And FY Ended 31 March 2026 And Any Other Matter. | - |
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-02-24 | Intimation Of Trading Approval For 371000 Equity Shares Of Face Value Rs. 10/- Each Allotted Pursuant To Conversion Of Warrants Issued On Preferential Basis From BSE Limited | - |
| 2026-02-05 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-02-04 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-04 | Unaudited Standalone Financial Results Of The Company For The Third Quarter And Nine Months Ended 31 December 2025 Subjected To Limited Review Of The Statutory Auditor Of The Company - Regulations 30 And 33 Of The Securities And Exchange Board Of India (L | - |
| 2026-02-04 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 4 February 2026 | - |
| 2026-02-04 | Change Of Name Of CompanyS Statutory Auditor | - |
| 2026-01-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-28 | Board Meeting Intimation for The Unaudited Financial Results For The Third Quarter And Nine Months Ending On 31-12-2025. | - |
| 2025-12-28 | Closure of Trading Window | - |
| 2025-12-17 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-17 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2025-11-08 | Unaudited Standalone Financial Results Of The Company Forthe Second Quarter And Half Year Ended 30 September2025 - Regulations 30 And 33 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2025-11-08 | Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 8 November 2025 | - |
| 2025-11-02 | Board Meeting Intimation for Consideration And Approval Of Unaudited Standalone Financial Results Of The Company For The Second Quarter And Half Year Ended 30 September 2025 | - |